InspireMD Inc. (NSPR)
| Market Cap | 33.95M |
| Revenue (ttm) | 3.18M |
| Net Income (ttm) | -12.84M |
| Shares Out | 7.91M |
| EPS (ttm) | -2.74 |
| PE Ratio | n/a |
| Forward PE | 11.70 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 44,663 |
| Open | 4.12 |
| Previous Close | 4.18 |
| Day's Range | 3.95 - 4.12 |
| 52-Week Range | 3.60 - 22.20 |
| Beta | 1.83 |
| Analysts | Strong Buy |
| Price Target | 16.50 (+310.4%) |
| Est. Earnings Date | Nov 8, 2021 |
About NSPR
InspireMD, Inc., a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia. The company offers CGuard carotid embolic prevention system for use in carotid artery applications; and MGuard Prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions. It is also developing ...
Financial Performance
In 2020, InspireMD's revenue was $2.49 million, a decrease of -33.22% compared to the previous year's $3.72 million. Losses were -$10.54 million, 5.02% more than in 2019.
Financial StatementsAnalyst Forecast
According to one analyst, the rating for InspireMD stock is "Strong Buy" and the 12-month stock price forecast is 16.50.
News
Best Penny Stocks to Buy Right Now? Here's 3 For Your Watchlist in October
Are these penny stocks on your watchlist right now? The post Best Penny Stocks to Buy Right Now?
InspireMD Receives Reimbursement Approval for CGuard™ Embolic Prevention System from the French National Authority fo...
TEL AVIV, Israel, Oct. 13, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), a global developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Dis...
2 Net Current Asset Value Stock Picks to Consider
There are some investors who purchase U.S.-listed stocks that are trading below their liquidation values because they believe they can get a huge return out of these stocks after the market has reapprai...
3 Penny Stocks Insiders Are Buying
When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overa...
InspireMD Announces Strong Second Quarter 2021 Financial Results
Revenue rebound, strong procedural recovery
InspireMD Enrolls and Treats First Patients at Ballad Health System in U.S. Registration C-Guardian Clinical Trial of...
TEL AVIV, Israel, July 23, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease (CAD...
InspireMD to Present at the LD Micro Virtual Invitational Conference on June 9, 2021
TEL AVIV, Israel, June 02, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq-CM: NSPR) developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by Carotid Artery Disea...
InspireMD Commences Trading on Nasdaq-CM
Ticker to remain NSPR Ticker to remain NSPR
InspireMD to Participate at the Investor Summit Conference and Present to Investors on May 17, 2021
TEL AVIV, Israel, May 14, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR) developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of ...
InspireMD Announces Appointment of Katie Arnold to Board of Directors
TEL AVIV, Israel, May 12, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of...
InspireMD Announces First Quarter 2021 Financial Results
Company Completes Up-List to Nasdaq Capital Market, with Trading Becoming Effective May 21, 2021
InspireMD Announces Stock Exchange Listing Transfer to Nasdaq
Ticker to remain NSPR Ticker to remain NSPR
InspireMD Appoints Acclaimed Interventional Cardiologist Kenneth Rosenfield, MD as Chair of its Newly Formed Scientif...
TEL AVIV, Israel, April 29, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of the stroke caused by carotid ar...
PreMarket Prep Stock Of The Day: InspireMD
Benzinga's PreMarket Prep airs every morning from 8-9 a.m. ET. During that fast-paced, highly informative hour, traders and investors tune in to get the major news of the day, the catalysts behind those...
NSPR Stock: What You Should Know About InspireMD Today
InspireMD has vastly reduced the number of its shares trading ahead of a likely move to a Nasdaq listed. Conversion of NSPR stock warrants and preferred shares will be more difficult now.
InspireMD Provides Corporate Update for Shareholders
TEL AVIV, Israel, April 19, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR, NSPR.WS, NSPR.WSB), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke cause...
Best Penny Stocks To Buy Today? 3 Stocks To Watch In April 2021
Penny Stocks Continue to Make Big Headway in April 2021 The post Best Penny Stocks To Buy Today? 3 Stocks To Watch In April 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | Penn...
InspireMD Announces 1-for-15 Reverse Stock Split
TEL AVIV, Israel, April 14, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR, NSPR.WS, NSPR.WSB), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke cause...
InspireMD CEO Marvin Slosman Issues Letter to Fellow Stockholders Urging Support of the Company's Plans to List its C...
TEL AVIV, Israel, March 22, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of the stroke caused by carotid ar...
InspireMD Announces Fourth Quarter and Year-End 2020 Financial Results
Management to host investor conference call today, March 9, at 8:30am ET Management to host investor conference call today, March 9, at 8:30am ET
InspireMD to Report Fourth Quarter and Year-End 2020 Financial Results on Tuesday, March 9, 2021 and Provide Corporat...
Earnings conference call to be held Tuesday, March 9, 2021 at 8:30 a.m. ET Earnings conference call to be held Tuesday, March 9, 2021 at 8:30 a.m. ET
InspireMD Engages Hart Clinical Consultants to Conduct Clinical Trial for CGuard Carotid Stent System in the United S...
TEL AVIV, Israel, Feb. 24, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery ...
InspireMD Appoints Leading Interventional Cardiologist Chris Metzger, M.D. as Principal Investigator for CGuard Regis...
TEL AVIV, Israel, Feb. 09, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery ...
InspireMD Announces Closing of an Upsized $20.7 Million Underwritten Public Offering and Full Exercise of Over-Allotm...
TEL AVIV, Israel, Feb. 08, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. ("InspireMD") (NYSE:NSPR), a medical device company focused on the development and commercialization of proprietary MicroNet stent pla...
InspireMD Announces Pricing of Upsized $18 Million Underwritten Public Offering
TEL AVIV, Israel, Feb. 04, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. ("InspireMD") (NYSE:NSPR), a medical device company focused on the development and commercialization of proprietary MicroNet stent pla...